ClearPoint Neuro, Inc. (CLPT) Form 8-K — Oct 28, 2026
$CLPTForm 8-KItems 2.02, 7.01, 9.01Filed Oct 28, 2026, 4:05 PM ET0001193125-26-436125Original filing
ClearPoint Neuro reported Q3 2026 revenue of $12.1 million, up 36% year-over-year, boosted by the IRRAflow portfolio acquired with IRRAS and a return to double-digit growth in biologics and drug delivery. Neurosurgery navigation and therapy revenue jumped 59% to $5.4 million, and capital equipment revenue hit a record $1.7 million, up 68%. The company raised its 2026 revenue guidance to $48.0-$50.0 million and ended the quarter with $46.2 million in cash after raising $22.0 million net from its at-the-market equity program.
Key figures
- Revenue
- 12075000
- Guidance
- 2026 revenue estimated between $48.0 million and $50.0 million
- Total Debt
- 50840000
- Revenue Yoy
- 36%
- Total Assets
- 112728000
- Cash Position
- 46200000
- Shares Outstanding
- 32051494
- Gross margin q3
- 58%
- Atm net proceeds
- 22000000
- Operating expenses q3
- 13400000
- Capital equipment growth
- 68%
- Gross margin prior year q3
- 63%
- Biologics drug delivery revenue
- 4900000
- Capital equipment software revenue
- 1700000
- Neurosurgery navigation therapy growth
- 59%
- Neurosurgery navigation therapy revenue
- 5400000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.